{ "module": "kr-companies", "itemId": "00878696", "title": "SK biopharmaceuticals Co., Ltd. (에스케이바이오팜 주식회사) — KOSPI 326030", "summary": "Korean listed company (에스케이바이오팜 주식회사, KOSPI 326030). Official DART corporate profile, KRW financial summary, and recent filings.", "data": { "corp_code": "00878696", "stock_code": "326030", "name_en": "SK biopharmaceuticals Co., Ltd.", "name_ko": "에스케이바이오팜 주식회사", "alternate_names": [ "에스케이바이오팜" ], "market": "KOSPI", "ceo_name": "이동훈", "business_registration_no": "1018662394", "corporate_registration_no": "1101114570720", "address": "경기도 성남시 분당구 판교역로 221", "homepage": "https://www.skbp.com/", "established_date": "2011-04-01", "fiscal_month": "12", "industry_code": "7011", "financials": { "fiscal_year": 2025, "basis": "CFS", "currency": "KRW", "revenue": 706740960308, "operating_income": 203938471064, "net_income": 253253847619, "total_assets": 1198308575535, "total_liabilities": 372039049706, "total_equity": 826269525829, "prior_year": { "fiscal_year": 2024, "revenue": 547596283214, "operating_income": 96339659521, "net_income": 226973435375, "total_assets": 1036810779623, "total_liabilities": 462826530311, "total_equity": 573984249312 }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773", "verified_at": "2026-11-01T02:28:16.948Z" }, "recent_filings": [ { "receipt_no": "20260923800342", "filed_date": "2026-09-23", "title_ko": "단일판매ㆍ공급계약체결", "title_en": "Conclusion of Single Sales Contract or Supply Contract", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260923800342" }, { "receipt_no": "20260917800227", "filed_date": "2026-09-17", "title_ko": "투자판단관련주요경영사항", "title_en": "Material Business Matters Related to Investment Decisions", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260917800227" }, { "receipt_no": "20260915800235", "filed_date": "2026-09-15", "title_ko": "최대주주등소유주식변동신고서", "title_en": "Report on Shares Change of Largest Shareholders", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260915800235" }, { "receipt_no": "20260915000042", "filed_date": "2026-09-15", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "이동훈", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260915000042" }, { "receipt_no": "20260915000040", "filed_date": "2026-09-15", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "유창호", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260915000040" }, { "receipt_no": "20260914800220", "filed_date": "2026-09-14", "title_ko": "단일판매ㆍ공급계약체결", "title_en": "Conclusion of Single Sales Contract or Supply Contract", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260914800220" }, { "receipt_no": "20260910800702", "filed_date": "2026-09-10", "title_ko": "기업설명회(IR)개최(안내공시)", "title_en": "Organization of Investor Relations Event", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260910800702" }, { "receipt_no": "20260910800675", "filed_date": "2026-09-10", "title_ko": "투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 수령)", "title_en": "Material Business Matters Related to Investment Decisions (뇌전증 신약 후보 물질 Opakalim의 미국 FDA 임상 2/3상 Partial Clinical Hold 통보 수령)", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260910800675" }, { "receipt_no": "20260831800329", "filed_date": "2026-08-31", "title_ko": "최대주주등소유주식변동신고서", "title_en": "Report on Shares Change of Largest Shareholders", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831800329" }, { "receipt_no": "20260831000159", "filed_date": "2026-08-31", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "이동훈", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831000159" }, { "receipt_no": "20260831000145", "filed_date": "2026-08-31", "title_ko": "임원ㆍ주요주주특정증권등소유상황보고서", "title_en": "Report on status of specific securities, etc. owned by executives and major shareholders", "filer": "유창호", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260831000145" }, { "receipt_no": "20260827000583", "filed_date": "2026-08-27", "title_ko": "대규모기업집단현황공시[분기별공시(개별회사용)]", "title_en": "Disclosure of Current Status of Large-scale Business Groups [Quarterly Disclosure (For individual company)]", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260827000583" }, { "receipt_no": "20260826000365", "filed_date": "2026-08-26", "title_ko": "[첨부추가]주요사항보고서(중요한자산양수도결정(기타))", "title_en": "[Added attachment]Report on Major Issues (중요한자산양수도결정(기타))", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260826000365" }, { "receipt_no": "20260826800162", "filed_date": "2026-08-26", "title_ko": "기업설명회(IR)개최(안내공시)", "title_en": "Organization of Investor Relations Event", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260826800162" }, { "receipt_no": "20260826800139", "filed_date": "2026-08-26", "title_ko": "투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약)", "title_en": "Material Business Matters Related to Investment Decisions (뇌전증 신약 후보 물질 Opakalim 등에 대한 라이선스 인 계약)", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260826800139" }, { "receipt_no": "20260818800303", "filed_date": "2026-08-18", "title_ko": "단일판매ㆍ공급계약체결", "title_en": "Conclusion of Single Sales Contract or Supply Contract", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260818800303" }, { "receipt_no": "20260814002274", "filed_date": "2026-08-14", "title_ko": "반기보고서 (2026.06)", "title_en": "Semi-annual Report (2026.06)", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814002274" }, { "receipt_no": "20260814000403", "filed_date": "2026-08-14", "title_ko": "지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항", "title_en": "Matters concerning payment amount for each payment method-payment period and Dispute Resolution Organization", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814000403" }, { "receipt_no": "20260805800117", "filed_date": "2026-08-05", "title_ko": "연결재무제표기준영업(잠정)실적(공정공시)", "title_en": "Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)", "filer": "에스케이바이오팜", "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260805800117" } ], "source_urls": { "company": "https://dart.fss.or.kr", "financials": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773", "filings": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260923800342" }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773", "verified_at": "2026-11-01T02:26:02.813Z", "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company." }, "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318000773", "verified_at": "2026-11-01T02:26:02.813Z", "updated_at": "2026-11-01T02:26:02.813Z", "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company." }